$697 Million is the total value of Soleus Capital Management, L.P.'s 72 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VRDN | Exit | VIRIDIAN THERAPEUTICS INC | $0 | – | -19,518 | -100.0% | -0.05% | – |
| RCKT | Exit | ROCKET PHARMACEUTICALS INC | $0 | – | -25,300 | -100.0% | -0.06% | – |
| PLRX | Exit | PLIANT THERAPEUTICS INC | $0 | – | -21,200 | -100.0% | -0.06% | – |
| Exit | DA32 LIFE SCNCE TEC ACQSTN C | $0 | – | -50,000 | -100.0% | -0.07% | – | |
| IMUX | Exit | IMMUNIC INC | $0 | – | -240,000 | -100.0% | -0.10% | – |
| Exit | IO BIOTECH INC | $0 | – | -288,119 | -100.0% | -0.11% | – | |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -13,400 | -100.0% | -0.12% | – |
| Exit | BRIDGEBIO PHARMA INCnote 2.500% 3/1 | $0 | – | -1,950,000 | -100.0% | -0.16% | – | |
| VSTM | Exit | VERASTEM INC | $0 | – | -1,644,500 | -100.0% | -0.19% | – |
| NVO | Exit | NOVO-NORDISK A Sadr | $0 | – | -14,100 | -100.0% | -0.19% | – |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -67,300 | -100.0% | -0.20% | – |
| EIGR | Exit | EIGER BIOPHARMACEUTICALS INC | $0 | – | -219,000 | -100.0% | -0.22% | – |
| INMD | Exit | INMODE LTD | $0 | – | -67,449 | -100.0% | -0.27% | – |
| OSUR | Exit | ORASURE TECHNOLOGIES INC | $0 | – | -565,000 | -100.0% | -0.29% | – |
| MIRM | Exit | MIRUM PHARMACEUTICALS INC | $0 | – | -135,618 | -100.0% | -0.39% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -72,000 | -100.0% | -0.46% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -5,587,789 | -100.0% | -0.72% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -27,000 | -100.0% | -0.73% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -23,200 | -100.0% | -0.84% | – |
| APEN | Exit | APOLLO ENDOSURGERY INC | $0 | – | -1,137,105 | -100.0% | -0.85% | – |
| NRIX | Exit | NURIX THERAPEUTICS INC | $0 | – | -504,144 | -100.0% | -0.89% | – |
| CSTL | Exit | CASTLE BIOSCIENCES INC | $0 | – | -297,840 | -100.0% | -1.06% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -1,025,200 | -100.0% | -1.33% | – |
| NTRA | Exit | NATERA INC | $0 | – | -275,673 | -100.0% | -1.64% | – |
| NVST | Exit | ENVISTA HOLDINGS CORPORATION | $0 | – | -480,000 | -100.0% | -2.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
| IRADIMED CORP | 16 | Q3 2023 | 5.8% |
| XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
| IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
| SURMODICS INC | 14 | Q3 2023 | 4.7% |
| NATERA INC | 13 | Q3 2023 | 3.9% |
| DEXCOM INC | 13 | Q2 2023 | 4.2% |
| NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
| CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
| LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.